Literature DB >> 28548128

Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.

Gregor Krings1, Nancy M Joseph1, Gregory R Bean1, David Solomon1, Courtney Onodera1, Eric Talevich1, Iwei Yeh2, James P Grenert1, Elizabeth Hosfield3, Emily D Crawford4, Richard C Jordan2,5, Annemieke van Zante1, Charles Zaloudek1, Sandra J Shin6, Yunn-Yi Chen1.   

Abstract

Secretory carcinomas of the breast are rare tumors with distinct histologic features, recurrent t(12;15)(p13;q25) translocation resulting in ETV6-NTRK3 gene fusion and indolent clinical behavior. Mammary analog secretory carcinomas arising in other sites are histopathologically similar to the breast tumors and also harbor ETV6-NTRK3 fusions. Breast secretory carcinomas are often triple (estrogen and progesterone receptor, HER2) negative with a basal-like immunophenotype. However, genomic studies are lacking, and whether these tumors share genetic features with other basal and/or triple negative breast cancers is unknown. Aside from shared ETV6-NTRK3 fusions, the genetic relatedness of secretory carcinomas arising in different sites is also uncertain. We immunoprofiled and sequenced 510 cancer-related genes in nine breast secretory carcinomas and six salivary gland mammary analog secretory carcinomas. Immunoprofiles of breast and salivary gland secretory carcinomas were similar. All the tumors showed strong diffuse MUC4 expression (n=15), and SOX10 was positive in all nine breast and in five out of six salivary gland tumors. All breast secretory carcinomas were triple negative or weakly ER-positive, and all tumors at both the sites expressed CK5/6 and/or EGFR, consistent with a basal-like phenotype. Sequencing revealed classic ETV6-NTRK3 fusion genes in all cases, including in carcinoma in situ of one breast tumor. Translocations were reciprocal and balanced in six out of nine breast and three out of six salivary gland tumors and were complex in three others. In contrast to most breast basal carcinomas, the mutational burden of secretory carcinomas was very low, and no additional pathogenic aberrations were identified in genes typically mutated in breast cancer. Five (56%) breast and two (33%) salivary gland tumors had simple genomes without copy number changes; the remainder had very few changes, averaging 1.3 per tumor. The ETV6-NTRK3 derivative chromosome was duplicated in one breast and one salivary gland tumor, and was the only copy number change in the latter. The findings highlight breast secretory carcinoma as a subtype more closely related to mammary analog secretory carcinoma than to basal/triple negative breast cancers of no special type. Lack of pathogenic mutations in common cancer-related genes suggests that ETV6-NTRK3 alone may suffice to drive these tumors and likely helps explain their indolent behavior.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28548128     DOI: 10.1038/modpathol.2017.32

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  81 in total

1.  Mammary analogue secretory carcinoma of the salivary glands with ETV6-NTRK3 gene fusion.

Authors:  André Fehr; Thomas Löning; Göran Stenman
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

2.  The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells.

Authors:  D H Wai; S R Knezevich; T Lucas; B Jansen; R J Kay; P H Sorensen
Journal:  Oncogene       Date:  2000-02-17       Impact factor: 9.867

3.  Secretory Carcinoma of the Skin Harboring ETV6 Gene Fusions: A Cutaneous Analogue to Secretory Carcinomas of the Breast and Salivary Glands.

Authors:  Justin A Bishop; Janis M Taube; Albert Su; Scott W Binder; Dmitry V Kazakov; Michal Michal; William H Westra
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

4.  Mammary analogue secretory carcinoma of salivary glands: a clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion.

Authors:  Yohei Ito; Kenichiro Ishibashi; Ayako Masaki; Kana Fujii; Yukio Fujiyoshi; Hideo Hattori; Daisuke Kawakita; Manabu Matsumoto; Satoru Miyabe; Kazuo Shimozato; Toshitaka Nagao; Hiroshi Inagaki
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

5.  Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity.

Authors:  Ashton Connor; Bayardo Perez-Ordoñez; Mary Shago; Alena Skálová; Ilan Weinreb
Journal:  Am J Surg Pathol       Date:  2012-01       Impact factor: 6.394

Review 6.  Secretory breast carcinoma: a clinicopathological and immunophenotypic study of 15 cases with a review of the literature.

Authors:  Dali Li; Xiuying Xiao; Wentao Yang; Ruohong Shui; Xiaoyu Tu; Hongfen Lu; Daren Shi
Journal:  Mod Pathol       Date:  2011-12-09       Impact factor: 7.842

7.  Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors.

Authors:  J M Bourgeois; S R Knezevich; J A Mathers; P H Sorensen
Journal:  Am J Surg Pathol       Date:  2000-07       Impact factor: 6.394

8.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Mucoepidermoid carcinoma of the breast.

Authors:  Luca Di Tommaso; Maria P Foschini; Teresa Ragazzini; Elisabetta Magrini; Adele Fornelli; Ian O Ellis; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2003-11-21       Impact factor: 4.064

10.  Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia.

Authors:  Johanna M Kralik; Wolfgang Kranewitter; Hans Boesmueller; Renate Marschon; Gertraud Tschurtschenthaler; Holger Rumpold; Kurt Wiesinger; Martin Erdel; Andreas L Petzer; Gerald Webersinke
Journal:  Diagn Pathol       Date:  2011-03-15       Impact factor: 2.644

View more
  17 in total

1.  TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.

Authors:  Ezra Y Rosen; Debra A Goldman; Jaclyn F Hechtman; Ryma Benayed; Alison M Schram; Emiliano Cocco; Sophie Shifman; Yixiao Gong; Ritika Kundra; James P Solomon; Alberto Bardelli; Maurizio Scaltriti; Alexander Drilon; Alexia Iasonos; Barry S Taylor; David M Hyman
Journal:  Clin Cancer Res       Date:  2019-12-23       Impact factor: 12.531

2.  Expression of upstream and downstream targets of mTOR pathway in seven cases of secretory carcinoma of salivary gland origin.

Authors:  Marcos Custódio; Bruno Tavares Sedassari; Albina Altemani; Maria Fernanda Setúbal Destro Rodrigues; Fábio Daumas Nunes; Suzana Cantanhede Orsini Machado de Sousa
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-06-23       Impact factor: 2.503

Review 3.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

4.  Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy.

Authors:  Alanna J Church; Monica L Calicchio; Valentina Nardi; Alena Skalova; Andre Pinto; Deborah A Dillon; Carmen R Gomez-Fernandez; Namitha Manoj; Josh D Haimes; Joshua A Stahl; Filemon S Dela Cruz; Sarah Tannenbaum-Dvir; Julia L Glade-Bender; Andrew L Kung; Steven G DuBois; Harry P Kozakewich; Katherine A Janeway; Antonio R Perez-Atayde; Marian H Harris
Journal:  Mod Pathol       Date:  2017-11-03       Impact factor: 7.842

5.  Identification and functional analysis of SOX10 phosphorylation sites in melanoma.

Authors:  Julia C Cronin; Stacie K Loftus; Laura L Baxter; Steve Swatkoski; Marjan Gucek; William J Pavan
Journal:  PLoS One       Date:  2018-01-09       Impact factor: 3.240

Review 6.  Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers.

Authors:  Yu Chen; Ping Chi
Journal:  J Hematol Oncol       Date:  2018-06-07       Impact factor: 17.388

Review 7.  Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.

Authors:  Susan J Hsiao; Ahmet Zehir; Anthony N Sireci; Dara L Aisner
Journal:  J Mol Diagn       Date:  2019-05-07       Impact factor: 5.568

Review 8.  Secretory carcinoma of the breast with multiple distant metastases in the brain and unfavorable prognosis: a case report and literature review.

Authors:  Hongping Tang; Lihua Zhong; Hongbing Jiang; Yan Zhang; Guannan Liang; Guoyan Chen; Gui'e Xie
Journal:  Diagn Pathol       Date:  2021-06-24       Impact factor: 2.644

9.  Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours.

Authors:  P Garrido; R Hladun; E de Álava; R Álvarez; F Bautista; F López-Ríos; R Colomer; F Rojo
Journal:  Clin Transl Oncol       Date:  2021-02-23       Impact factor: 3.405

10.  WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer.

Authors:  Richard J McGregor; You-Ying Chau; Timothy J Kendall; Mara Artibani; Nicholas Hastie; Patrick W F Hadoke
Journal:  Br J Cancer       Date:  2018-10-30       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.